Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Step 1:~* ECOG 0-2~* Histologically verified neuroendocrine tumors with a Ki67 of at least 20 % or at least 20 mitoses/high power fields. If the tissue on which this determination is based is several years old, the investigator should consider the option of acquiring a new determination, especially if the behaviour of the tumor has changed since diagnosis~* Metastatic disease where complete resection is not considered possible or feasible~* Measurable disease~* Radiological disease progression during the last 14 months~* The largest metastases should have an uptake of 111In-octreotide that is greater than the uptake in the liver by planar scintigraphy. Metastases that are small, or located centrally, can be evaluated by SPECT to enable a correct estimation of the relative uptake. The majority of the tumor burden must demonstrate an increased uptake for lutetium-treatment to be considered~* Stable dose of somatostatin analogue for the past 3 months~* Estimated survival more than 6 months~* ANC more than 1.5 x 10 9/L~* Bilirubin less than 1.5 x upper limit of normal~* GFR more than 50 ml/min.~* Signed written informed concent~Step 2:~* Continues to fulfill all of the inclusion criteria, and none of the exclusion criteria, from step 1~* A maintained GFR (less than 40 % decrease compared to baseline AND GFR more than 50 ml/min)~* The treatment in step 1 have been administered with a maximal interval of 12 weeks~* Age under 70 years~Exclusion Criteria:~Step 1:~* Performance Status ECOG 3-4~* Proliferation index (Ki67) more than 20 % or more than 20 mitoses/hpf~* Loco-regional treatment during the last 3 months involving all of the measurable lesions~* Chemotherapy during the last 3 months, or longer if persisting toxicity exists. Earlier treatment with mTORi or TKI is permitted~* Other concommitant nephrotoxic treatment~* Modifications of the somatostatine dose in the last 3 months~* Serious heart disease~* Previous radiotherapy including more than 25 % of active bone marrow volume~* Pregnancy and lactation~* Extensive liver metastases (more than 50 % of liver volume)~* Symptomatic CNS metastases requiring corticosteroid treatment~* Ongoing treatment with interferon. This treatment should be suspended a minimum of 4 weeks before treatment with 177Lu-DOTA-TATE, or longer if there is persisting signs of toxicity~* Patients who have another metastatic tumor diagnosis~Step 2:~* Progressive disease since start of study treatment~* Organ toxicity grade 3-4 during step 1~* Serious hematological toxicity during previous treatment cycles (ANC less than 0.5 x 10 9 or platelets less than 50.0 x 10 9)~* Longstanding diabetes (more than 8 years). Patients with a well-controlled diabetes with a history of less than 8 years and a blood pressure less than 130/80 and no albuminuria (albumin/creatinine index)can be included~* Hypertension, i.e. more than 160/90 (for diabetics more than 130/80). Antihypertensive pharmacological treatment is permitted as long as there is no manifest albuminuria~* Previous liver embolisation~* Previous chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 177Lu-DOTA-TATE (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).